M. Trudeau

发表

Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer.

Melania Pintilie, A. Fyles, M. Pintilie, 2004, The New England journal of medicine.

Prevalence and Workplace Drivers of Burnout in Cancer Care Physicians in Ontario, Canada

G. Bauman, A. Eisen, C. Fox, 2021, JCO oncology practice.

Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence

S. Narod, K. Pritchard, P. Sun, 2007, Clinical Cancer Research.

Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study.

B. Hoffman, P. Goodwin, K. Pritchard, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biological Significance of Occult Micrometastases in Histologically Negative Axillary Lymph Nodes in Breast Cancer Patients Using the Recent American Joint Committee on Cancer Breast Cancer Staging System

K. Pritchard, D. McCready, J. Chapman, 2006, The breast journal.

Clinical behavior of untreated axillary nodes after local treatment for primary breast cancer

D. McCready, J. Chapman, M. Trudeau, 1996, Annals of Surgical Oncology.

Early prediction of therapy responses and outcomes in breast cancer patients using quantitative ultrasound spectral texture

Martin J. Yaffe, Gregory J. Czarnota, Michael C. Kolios, 2014, Oncotarget.

Adjuvant endocrine therapy of breast cancer.

K. Pritchard, M. Trudeau, 1992, Cancer treatment and research.

Quantitative ultrasound radiomics in predicting response to neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from multi‐institutional study

Michael C. Kolios, G. Stanisz, W. Yang, 2020, Cancer medicine.

Cost‐effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer

M. Trudeau, N. Mittmann, N. Risebrough, 2007, Cancer.

Risk of menopause during the first year after breast cancer diagnosis.

P. Goodwin, K. Pritchard, M. Trudeau, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantitative ultrasound radiomics for therapy response monitoring in patients with locally advanced breast cancer: Multi-institutional study results

Michael C. Kolios, G. Stanisz, W. Yang, 2020, PloS one.

Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review.

A. Eisen, K. Pritchard, M. Trudeau, 2008, Cancer treatment reviews.

Closing the personalized medicine information gap: HER2 test documentation practice.

C. Earle, D. Marshall, M. Trudeau, 2013, The American journal of managed care.

FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.

J. Bergh, F. Wiklund, W. Eiermann, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ambulatory Toxicity Management (AToM) in patients receiving adjuvant or neo-adjuvant chemotherapy for early stage breast cancer - a pragmatic cluster randomized trial protocol

C. Earle, M. Trudeau, M. Krzyzanowska, 2019, BMC Cancer.

Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.

M. Somerfield, A. Wolff, G. Lyman, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant taxane-based chemotherapy for early stage breast cancer: a real-world comparison of chemotherapy regimens in Ontario

Kelvin K. W. Chan, C. Earle, A. Eisen, 2015, Breast Cancer Research and Treatment.

Population-based assessment of emergency room visits and hospitalizations among women receiving adjuvant chemotherapy for early breast cancer.

C. Earle, R. Moineddin, A. Eisen, 2015, Journal of oncology practice.

Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.

M. Clemons, T. Vandenberg, D. Rayson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk o f M enopause D uring t he F irst Y ear A fter B reast Cancer D iagnosis

P. Goodwin, K. Pritchard, M. Trudeau, 1999 .

Cost effectiveness of tac versus fac in adjuvant treatment of node-positive breast cancer

M. Trudeau, N. Mittmann, S. Verma, 2010, Current oncology.

Economic evaluation of hormonal therapies for postmenopausal women with estrogen receptor-positive early breast cancer in Canada.

M. Trudeau, M. Krahn, M. Krahn, 2015, Current oncology.

Survival Differences Observed in Metastatic Breast Cancer Patients Treated With Capecitabine When Compared With Vinorelbine After Pretreatment With Anthracycline and Taxane

J. Mackey, S. Verma, G. Dranitsaris, 2007, American journal of clinical oncology.

A framework for the organization and delivery of systemic treatment

T. Vandenberg, M. Trudeau, E. Green, 2009, Current oncology.

Adjuvant T reatment a nd O nset o f M enopause P redict W eight Gain A fter B reast C ancer D iagnosis

P. Goodwin, K. Pritchard, D. McCready, 1999 .

Population-based health care cost estimates related to breast cancer by staging.

C. Earle, R. Saskin, K. Dainty, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Key components of intravenous chemotherapy labeling: A systematic review and practice guideline

M. Trudeau, E. Green, Y. Ko, 2011, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Impact of rarity on Canadian oncology health technology assessment and funding

Kelvin K. W. Chan, A. Eisen, G. Darling, 2020, International Journal of Technology Assessment in Health Care.

Tumor RNA disruption predicts survival benefit from breast cancer chemotherapy

K. Pritzker, M. Trudeau, L. Shepherd, 2015, Breast Cancer Research and Treatment.

Is leptin a mediator of adverse prognostic effects of obesity in breast cancer?

I. G. Fantus, P. Goodwin, K. Pritchard, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study

B. Hoffman, P. Goodwin, K. Pritchard, 2002 .

P. Goodwin, K. Pritchard, M. Trudeau, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diet and breast cancer: evidence that extremes in diet are associated with poor survival.

P. Goodwin, K. Pritchard, M. Trudeau, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diet a nd B reast C ancer: E vidence T hat E xtremes i n D iet A re Associated W ith P oor S urvival

P. Goodwin, K. Pritchard, M. Trudeau, 2003 .

Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis.

P. Goodwin, K. Pritchard, D. McCready, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic significance of circulating tumour cells enumerated after filtration enrichment in early and metastatic breast cancer patients

Liying Zhang, M. Trudeau, Alexander Marks, 2006, Breast Cancer Research and Treatment.

Fast ing Insul in and Outcome in Early-Stage Breast Cancer : Resul ts of a Prospect i ve Cohort Study

B. Hoffman, P. Goodwin, K. Pritchard, 2001 .

Cancer diagnostic assessment programs: standards for the organization of care in Ontario

J. Srigley, L. Rabeneck, T. Oliver, 2009, Current oncology.

International variability in the reimbursement of cancer drugs by publically funded drug programs.

M. Trudeau, B. Godman, S. Gavura, 2012, Current oncology.

Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).

E. Eisenhauer, M. Trudeau, M. Crump, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Factors associated with imaging in patients with early breast cancer after initial treatment.

M. Trudeau, C. Booth, M. Krzyzanowska, 2018, Current oncology.

Associations among socioeconomic status, patterns of care, and outcomes in breast cancer patients in a universal health care system: Ontario's experience

Kelvin K. W. Chan, M. Trudeau, A. Kumachev, 2016, Cancer.

Decisional Support throughout the Cancer Journey for Older Women Diagnosed with Early Stage Breast Cancer: A Single Institutional Study

A. Kiss, E. Warner, D. Feldman-Stewart, 2014, Journal of Cancer Education.

Conditional approval of cancer drugs in Canada: accountability and impact on public funding.

M. Trudeau, M. Cheung, A. Chambers, 2019, Current oncology.

Setting Quality Improvement Priorities for Women Receiving Systemic Therapy for Early-Stage Breast Cancer by Using Population-Level Administrative Data.

M. Trudeau, C. Booth, M. Krzyzanowska, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safe Administration of Systemic Cancer Therapy: Introduction and General Methods

M. Trudeau, V. Kukreti, S. Singh, 2012 .

Retrospective analysis of VES-13 questionnaires in the Senior Women's Breast Cancer Clinic at Sunnybrook Health Sciences, Toronto, Ontario, Canada.

Bonnie J Bristow, E. Szumacher, M. Trudeau, 2022, Journal of geriatric oncology.

Prediction of breast cancer–related outcomes with the Edmonton Symptom Assessment Scale: A literature review

M. Trudeau, N. Coburn, H. Lam, 2020, Supportive Care in Cancer.

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer

H. Gómez, K. Blackwell, A. Manikhas, 2012, Breast Cancer Research and Treatment.

A priori prediction of breast tumour response to chemotherapy using quantitative ultrasound imaging and artificial neural networks

W. Tran, E. Rakovitch, A. Eisen, 2019, Oncotarget.

Regional Models of Care for Systemic Treatment

T. Vandenberg, M. Trudeau, E. Green, 2011 .

Safe handling of parenteral cytotoxics: recommendations for ontario.

M. Trudeau, E. Green, G. Macartney, 2009, Journal of oncology practice.

Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis

M. Mamdani, C. Bell, S. Peacock, 2014, BMC Cancer.

Adjuvant Taxane Therapy for Women with Early-stage, Invasive Breast Cancer: A Clinical Practice Guideline

A. Eisen, M. Trudeau, Hans Messersmith, 2006 .

Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.

Sung-Bae Kim, W. Gradishar, N. Masuda, 2019, Journal of Clinical Oncology.

Population-based home care services in breast cancer: utilization and costs.

C. Earle, R. Saskin, K. Dainty, 2012, Current oncology.

Clinical Outcomes of Single Versus Double Hormone Receptor–Positive Breast Cancer Patients Treated With Neoadjuvant Chemotherapy

A. Kiss, M. Trudeau, S. Nofech-Mozes, 2018, Clinical breast cancer.

The value of personalizing medicine: medical oncologists' views on gene expression profiling in breast cancer treatment.

Y. Bombard, L. Rozmovits, D. Marshall, 2015, The oncologist.

Factors influencing arm and axillary symptoms after treatment for node negative breast carcinoma

A. Fyles, S. Narod, D. McCready, 2003, Cancer.

Bisphosphonate use for the management of breast cancer patients with bone metastases: A survey of Canadian Medical Oncologists

Annemarie Cesta, S. Verma, G. Dranitsaris, 2004, Supportive Care in Cancer.

Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).

C. Hudis, M. Blaney, I. C. Tudor, 2015 .

Cost-utility analysis of 21-gene assay for node-positive early breast cancer.

A. Eisen, M. Trudeau, W. Isaranuwatchai, 2019, Current oncology.

Reply to L. Del Mastro and A. Prat.

M. Somerfield, A. Wolff, G. Lyman, 2017, Journal of Clinical Oncology.

A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes.

D. Tu, D. Walde, M. Blackstein, 2007, Annals of Oncology.

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Sung-Bae Kim, W. Gradishar, M. Yamaguchi, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imaging , Diagnosis , Prognosis Quantitative Ultrasound Evaluation of Tumor Cell Death Response in Locally Advanced Breast Cancer Patients Receiving Chemotherapy

Michael C. Kolios, M. Yaffe, S. Verma, 2013 .

Chemotherapy in Locally Advanced Breast Cancer Patients Receiving Quantitative Ultrasound Evaluation of Tumor Cell Death Response

Michael C. Kolios, M. Yaffe, S. Verma, 2013 .

Pilot Study on the Utility of Circulating HER2/Neu Levels in the Serum of Breast Cancer Patients

F. Lu, A. Seth, M. Trudeau, 2019, AntiCancer Research.

Establishing achievable benchmarks for quality improvement in systemic therapy for early‐stage breast cancer

M. Trudeau, C. Booth, M. Krzyzanowska, 2017, Cancer.

Health system costs for stage-specific breast cancer: a population-based approach.

C. Earle, R. Saskin, K. Dainty, 2014, Current oncology.

Early Changes in Quantitative Ultrasound Imaging Parameters during Neoadjuvant Chemotherapy to Predict Recurrence in Patients with Locally Advanced Breast Cancer

A. Eisen, M. Trudeau, G. Czarnota, 2021, Cancers.

Capecitabine in Stage IV Breast Cancer

M. Trudeau, E. Tomiak, S. Verma, 2003 .

Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.

E. Eisenhauer, B. Norris, T. Vandenberg, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer: pragmatic, cluster randomised trial

C. Earle, T. Vandenberg, M. Trudeau, 2021, BMJ.

The Perceptions and Expectations of Older Women in the Establishment of the Senior Women’s Breast Cancer Clinic (SWBCC): a Needs Assessment Study

Bonnie J Bristow, E. Szumacher, M. Trudeau, 2017, Journal of Cancer Education.

Utilization of Immunotherapy in Patients with Cancer Treated in Routine Care Settings: A Population-Based Study Using Health Administrative Data

G. Rodrigues, M. Trudeau, M. Krzyzanowska, 2022, The Oncologist.

Comparison of Use of Neoadjuvant Systemic Treatment for Breast Cancer and Short-term Outcomes Before vs During the COVID-19 Era in Ontario, Canada

A. Eisen, J. Irish, Siddharth Singh, 2022, JAMA network open.

Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer.

S. Dahrouge, K. Pritchard, M. Trudeau, 1990, Seminars in oncology.

Epirubicin in combination with the taxanes.

M. Trudeau, O. Pagani, 2001, Seminars in oncology.

Phase II study of weekly edatrexate as first-line chemotherapy for metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group study.

E. Eisenhauer, R. Buckman, B. Norris, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Henrietta Banting Breast Centre database: a model for clinical research utilizing a hospital-based inception cohort.

K. Pritchard, J. Chapman, M. Trudeau, 1995, Journal of clinical epidemiology.

The predictive value of ERICA in breast cancer recurrence. A univariate and multivariate analysis.

W. Hanna, M. Trudeau, J. Chapman, 1993, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

The standardization of estrogen receptors

K. Pritchard, D. McCready, J. Chapman, 1993, The Journal of Steroid Biochemistry and Molecular Biology.

Docetaxel: a new active agent in the therapy of metastatic breast cancer.

P. Fumoleau, M. Trudeau, A. Seidman, 1997, Expert opinion on investigational drugs.

First‐line treatment of metastatic breast cancer

M. Trudeau, 1996, Anti-cancer drugs.

Docetaxel (Taxotere): an overview of first-line monotherapy.

M. Trudeau, 1995, Seminars in oncology.

Preliminary results of a randomized study of tamoxifen alone or tamoxifen and breast radiation in women over 50 years of age with T1/2 N0 disease

A. Fyles, M. Pintilie, D. McCready, 2001 .

Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of respon

John M.L. Ebos, Mark Clemons, Robert Buckman, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I-II study of DalCM-P [daily dalteparin (Dal), cyclophosphamide (C) and prednisone (P) and bi-weekly methotrexate (M)] as therapy for metastatic breast cancer (MBC)

R. Kerbel, R. Buckman, M. Clemons, 2005 .

Development and Testing of an Adjuvant Radiotherapy Decision Aid for Older Women Diagnosed with Stage I Breast Cancer: A Pilot Study

E. Szumacher, M. Trudeau, I. Menjak, 2020, Cureus.

Combined fine-needle aspiration, physical examination and mammography in the diagnosis of palpable breast masses: their relation to outcome for women with primary breast cancer.

E. Fishell, D. McCready, J. Chapman, 1996, Canadian journal of surgery. Journal canadien de chirurgie.

Home care utilization and costs in stage IV lung cancer: a Canadian public payer experience

C. Earle, M. Trudeau, N. Leighl, 2014 .

End-of-life home care utilization and costs in patients with advanced colorectal cancer.

C. Earle, R. Saskin, K. Dainty, 2014, The Journal of community and supportive oncology.

Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer—A Literature Review

A. Eisen, M. Trudeau, D. Mata, 2022, Current oncology.

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial.

R. Bose, H. Rugo, D. Tripathy, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Assessment of communication gaps among referring physicians and the multi-disciplinary team at the senior women breast Cancer clinic (SWBCC), Sunnybrook health sciences Centre, Toronto, Ontario, Canada.

Bonnie J Bristow, E. Szumacher, M. Trudeau, 2020, Journal of geriatric oncology.

5th International Symposium on Focused Ultrasound

Matthew E. Downs, Gregory T. Clement, Chang Kyu Park, 2016, Journal of Therapeutic Ultrasound.

Population-based utilization of radiation therapy by a Canadian breast cancer cohort.

C. Earle, R. Saskin, M. Trudeau, 2014, Current oncology.

A randomized trial of tamoxifen with or without breast radiation in women with early breast cancer 50 years of age and over

A. Fyles, M. Pintilie, D. McCready, 2004 .

Impact of body mass index on survival in women receiving chemotherapy for early breast cancer

A. Eisen, M. Trudeau, R. Pezo, 2022, Breast Cancer Research and Treatment.

Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study.

G. Dranitsaris, M. Clemons, M. Trudeau, 2007, The journal of supportive oncology.

Optimizing adjuvant breast cancer chemotherapy: rationale for the MA.21 study.

M. Trudeau, 2001, Oncology.

Cost Utility Analysis of First-Line Hormonal Therapy in Advanced Breast Cancer: Comparison of Two Aromatase Inhibitors to Tamoxifen

G. Dranitsaris, M. Trudeau, S. Verma, 2003, American journal of clinical oncology.

A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer

E. Winer, Zhou Zhu, P. Morris, 2020, Clinical Cancer Research.

What is the best chemotherapy treatment option for anthracycline and taxane pretreated metastatic breast cancer?

J. Mackey, S. Verma, G. Dranitsaris, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update.

M. Somerfield, A. Wolff, G. Lyman, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reimbursement recommendations for cancer drugs supported by phase II evidence in Canada.

M. Trudeau, N. Mittmann, M. Cheung, 2020, Current oncology.

The impact of pricing strategy on the costs of oral anti‐cancer drugs

Kelvin K. W. Chan, M. Trudeau, M. Cheung, 2019, Cancer medicine.

Developing the Breast Utility Instrument to Measure Health-Related Quality-of-Life Preferences in Patients with Breast Cancer: Selecting the Item for Each Dimension

N. Mitsakakis, M. Trudeau, M. Krahn, 2022, MDM policy & practice.

Sensitivity of BRCA‐1‐Related Breast Cancer to Neoadjuvant Chemotherapy: Practical Implications

E. Warner, M. Trudeau, C. Holloway, 2003, The breast journal.

Pegylated liposomal doxorubicin (PLD) plus cyclophosphamide as 1st-line therapy for metastatic breast cancer in patients previously treated with anthracyclines

T. Vandenberg, D. Rayson, M. Trudeau, 2005 .

Evaluating an oncology systemic therapy computerized physician order entry system using international guidelines.

Sonal Gandhi, M. Trudeau, S. Gandhi, 2014, Journal of oncology practice.

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.

Peter Schmid, Rita Nanda, Hirdesh Uppal, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

E. Rutgers, M. Piccart, C. Denkert, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases

K. Hynynen, N. Lipsman, C. Hamani, 2021, Science Translational Medicine.

Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study

K. Hynynen, N. Lipsman, A. Bethune, 2019, Scientific Reports.

Pattern of metastatic spread in triple-negative breast cancer

S. Narod, P. Sun, M. Trudeau, 2009, Breast Cancer Research and Treatment.

Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin.

K. Pritchard, M. Trudeau, D. Stewart, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.

A. Eisen, M. Trudeau, S. Gandhi, 2015, Current oncology.

Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.

A. Eisen, M. Trudeau, S. Gandhi, 2014, Current oncology.

Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study.

D. Horsman, W. Foulkes, Z. Aziz, 2008, Cancer research.

An investigation of cut-points for primary breast cancer oestrogen and progesterone receptor assays

W. Hanna, K. Pritchard, D. McCready, 1996, The Journal of Steroid Biochemistry and Molecular Biology.

Communication – the foundation for collaborative relationships amongst providers, and between providers and patients: A case in breast and colorectal cancer

M. Trudeau, P. Lazure, R. Gryfe, 2014 .

Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations.

P. Goodwin, K. Pritchard, M. Trudeau, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes

B. Hoffman, P. Goodwin, K. Pritchard, 2002, Breast Cancer Research and Treatment.

Selection of adjuvant chemotherapy for treatment of node-positive breast cancer.

K. Gelmon, J. Mackey, K. Pritchard, 2005, The Lancet. Oncology.

Endometrial evaluation with transvaginal US and hysterosonography in asymptomatic postmenopausal women with breast cancer receiving tamoxifen.

L. Manchul, M. Trudeau, K. Fong, 2001, Radiology.

Evaluation of neoadjuvant chemotherapy response in women with locally advanced breast cancer using ultrasound elastography.

Ali Sadeghi-Naini, Gregory J Czarnota, Martin J Yaffe, 2013, Translational oncology.

Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.

S. Verma, G. Dranitsaris, M. Clemons, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.

M. Trudeau, K. Chan, E. Lee, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Outcome of patients with pregnancy during or after breast cancer: a review of the recent literature.

M. Trudeau, J. Raphael, K. Chan, 2014, Current oncology.

Access to cancer drugs in Canada: looking beyond coverage decisions.

A. Culyer, S. Morgan, P. Coyte, 2011, Healthcare policy = Politiques de sante.

F a s t i n g I n s u l i n and O utcome i n E arly-Stage B reast Cancer: R esults o f a P rospective C ohort S tudy

B. Hoffman, P. Goodwin, K. Pritchard, 2002 .

Patterns in target-directed breast cancer research

M. Trudeau, C. Simmons, S. Torres, 2016, SpringerPlus.

Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen.

E. Warner, I. Andrulis, P. Goss, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Prediction of chemotherapy response in breast cancer patients at pre-treatment using second derivative texture of CT images and machine learning

F. Wright, M. Trudeau, G. Czarnota, 2021, Translational oncology.

Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial

Sung-Bae Kim, W. Gradishar, R. Bose, 2021, The oncologist.

A population-based study of the epidemiology of pancreatic cancer: a brief report.

C. Earle, K. Dainty, M. Trudeau, 2015, Current oncology.

HER-2 and topoisomerase II as predictors of response to chemotherapy.

F. O'Malley, K. Pritchard, M. Trudeau, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine in the management of metastatic breast cancer: a systematic review

M. Trudeau, Hans Messersmith, S. Dent, 2008, Breast Cancer Research and Treatment.

The role of the taxanes in the management of metastatic breast cancer

T. Oliver, K. Pritchard, M. Trudeau, 2003 .

An overview of phase II studies of docetaxel in patients with metastatic breast cancer.

E. Eisenhauer, M. Trudeau, E. A. Eisenhauer, 1995, European journal of cancer.

Pan-Canadian Oncology Drug Review (pCODR): A unique model to support harmonization of cancer drug funding decisions in Canada.

M. Trudeau, A. Chambers, H. Mai, 2018, Journal of Clinical Oncology.

Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review.

K. Pritchard, D. McCready, M. Trudeau, 2008, Cancer treatment reviews.

Abstract GS4-07: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer

E. Winer, P. Morris, I. C. Tudor, 2017 .

Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.

Mike Paulden, Murray Krahn, B. Pham, 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Optimal systemic therapy for early breast cancer in women: a clinical practice guideline.

A. Eisen, M. Trudeau, S. Gandhi, 2014, Current oncology.

Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise

A. Denburg, Marianne Taylor, M. Trudeau, 2021, Current oncology.

Neoadjuvant taxanes in the treatment of non-metastatic breast cancer: a systematic review.

M. Clemons, M. Trudeau, S. Sinclair, 2005, Cancer treatment reviews.

Prognostic factors affecting the natural history of node-negative breast cancer

I. Andrulis, K. Pritchard, D. McCready, 2004, Breast Cancer Research and Treatment.

Radiation recall dermatitis with abemaciclib developing a year after radiotherapy

A. Sahgal, H. Soliman, M. Trudeau, 2021 .

Radiomics in predicting recurrence for patients with locally advanced breast cancer using quantitative ultrasound

Michael C. Kolios, W. Tran, A. Eisen, 2020, Oncotarget.

Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.

S. Verma, E. Warner, A. Eisen, 2018, The oncologist.

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update.

M. Somerfield, A. Wolff, G. Lyman, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.

A. Eisen, Philippe Bédard, K. Pritchard, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The influence of gene expression profiling on decisional conflict in decision making for early-stage breast cancer chemotherapy.

Y. Bombard, D. Marshall, M. Trudeau, 2016, European journal of cancer.

Patients' perceptions of gene expression profiling in breast cancer treatment decisions.

Y. Bombard, L. Rozmovits, D. Marshall, 2014, Current oncology.

Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers

S. Narod, P. Sun, M. Trudeau, 2009, Breast Cancer Research and Treatment.

The role of quantitative estrogen receptor status in predicting tumor response at surgery in breast cancer patients treated with neoadjuvant chemotherapy

F. Lu, M. Trudeau, S. Gandhi, 2017, Breast Cancer Research and Treatment.

Time to disease recurrence in basal‐type breast cancers

S. Narod, P. Sun, M. Trudeau, 2009, Cancer.

Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

R. Bose, H. Rugo, C. Singer, 2022, Breast.

Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.

P. LoRusso, M. Desilvio, S. Johnston, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

How do women trade-off benefits and risks in chemotherapy treatment decisions based on gene expression profiling for early-stage breast cancer? A discrete choice experiment

Y. Bombard, D. Marshall, M. Trudeau, 2016, BMJ Open.

Access to personalized medicine: factors influencing the use and value of gene expression profiling in breast cancer treatment.

Y. Bombard, L. Rozmovits, D. Marshall, 2014, Current oncology.

Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D

Kelvin K. W. Chan, M. Trudeau, W. Wong, 2015, Breast Cancer Research and Treatment.

Bringing diarrhea under CONTROL: dose escalation reduces neratinib-associated diarrhea and improves tolerability in HER2-positive early-stage breast cancer

D. Tripathy, M. Trudeau, A. Brufsky, 2021 .

Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8.

D. Osoba, P. Goss, B. Norris, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantitative Ultrasound Evaluation of Tumor Cell Death Response in Locally Advanced Breast Cancer Patients Receiving Chemotherapy

Michael C. Kolios, Michael C Kolios, Ali Sadeghi-Naini, 2013, Clinical Cancer Research.

Clinical utility of multigene profiling assays in early-stage breast cancer.

A. Eisen, S. Kamel‐Reid, Philippe Bédard, 2017, Current oncology.

Polymorphisms in folate metabolizing enzymes and transport proteins and the risk of breast cancer

S. Narod, J. Kotsopoulos, D. McCready, 2008, Breast Cancer Research and Treatment.

Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012.

D. Mould, E. Keystone, A. Lubiniecki, 2012, Biologicals : journal of the International Association of Biological Standardization.

Systemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.

A. Eisen, M. Trudeau, S. Gandhi, 2014, Current oncology.

Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside.

M. Trudeau, W. Hanna, H. Kahn, 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

HER2/neu in systemic therapy for women with breast cancer: a systematic review

F. O'Malley, K. Pritchard, M. Trudeau, 2008, Breast Cancer Research and Treatment.

Developing the Breast Utility Instrument, a preference-based instrument to measure health-related quality of life in women with breast cancer: Confirmatory factor analysis of the EORTC QLQ-C30 and BR45 to establish dimensions

A. Davis, N. Mitsakakis, M. Trudeau, 2022, PloS one.

The impact of cancer drug wastage on economic evaluations

Kelvin K. W. Chan, M. Trudeau, M. Cheung, 2017, Cancer.

Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.

K. Blackwell, M. Desilvio, S. Johnston, 2009, The Lancet. Oncology.

Adjusting For Drug Wastage In Economic Evaluations Of New Therapies For Hematologic Malignancies: A Systematic Review Of The Literature and Implications

Kelvin K. W. Chan, M. Trudeau, A. Prica, 2013 .

The effect of melatonin on sleep and quality of life in patients with advanced breast cancer

A. Kiss, A. Eisen, M. Clemons, 2016, Supportive Care in Cancer.

Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study

Kelvin K. W. Chan, C. Earle, G. Tomlinson, 2016, Breast Cancer Research and Treatment.

Management of Ductal Carcinoma in Situ of the Breast: A Clinical Practice Guideline

D. McCready, M. Trudeau, C. Holloway, 2006 .

Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis

M. Mamdani, C. Bell, S. Peacock, 2014, BMC Cancer.

The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study.

C. Earle, A. Yan, M. Trudeau, 2016, Journal of the National Cancer Institute.

Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes

Kelvin K. W. Chan, C. Earle, A. Yan, 2020, Breast Cancer Research and Treatment.

A priori prediction of response in multicentre locally advanced breast cancer (LABC) patients using quantitative ultrasound and derivative texture methods

Michael C. Kolios, W. Yang, W. Tran, 2021, Oncotarget.

Chemotherapy-Response Monitoring of Breast Cancer Patients Using Quantitative Ultrasound-Based Intra-Tumour Heterogeneities

Gregory J. Czarnota, Michael C. Kolios, Ali Sadeghi-Naini, 2017, Scientific Reports.

Stage at Diagnosis and Comorbidity Influence Breast Cancer Survival in First Nations Women in Ontario, Canada

M. Trudeau, A. Sheppard, A. Chiarelli, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Gait Speed vs. VES-13: A Pilot Study Comparing Screening Tools to Determine the Need for a Comprehensive Geriatric Assessment in Senior Women with Breast Cancer.

F. Wright, E. Szumacher, M. Trudeau, 2019, Journal of medical imaging and radiation sciences.

A priori Prediction of Neoadjuvant Chemotherapy Response and Survival in Breast Cancer Patients using Quantitative Ultrasound

Mehrdad J. Gangeh, Gregory J. Czarnota, Ali Sadeghi-Naini, 2017, Scientific Reports.

Quantitative ultrasound assessment of breast tumor response to chemotherapy using a multi-parameter approach

Gregory J. Czarnota, Ali Sadeghi-Naini, Lakshmanan Sannachi, 2016, Oncotarget.

The Role of Trastuzumab (Herceptin ) in the Treatment of Women with HER2/neu-overexpressing Metastatic Breast Cancer

M. Trudeau, M. Crump, S. Sinclair, 2005 .

Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study--NCIC CTG MA.5.

W. Parulekar, V. Bramwell, K. Pritchard, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MRI texture features from tumor core and margin in the prediction of response to neoadjuvant chemotherapy in patients with locally advanced breast cancer

Michael C. Kolios, G. Stanisz, A. Sahgal, 2021, OncoTarget.

Adherence to human epidermal growth factor receptor-2 testing and adjuvant trastuzumab treatment guidelines in Ontario

C. Earle, D. Marshall, M. Trudeau, 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer.

C. Earle, C. de Oliveira, M. Trudeau, 2022, JAMA oncology.

Enumeration of Circulating Tumor Cells in the Blood of Breast Cancer Patients After Filtration Enrichment: Correlation with Disease Stage

Claire Holloway, J. Blondal, D. McCready, 2004, Breast Cancer Research and Treatment.

Towards an optimal multidisciplinary approach to breast cancer treatment for older women.

E. Szumacher, M. Trudeau, I. Menjak, 2015, Canadian oncology nursing journal = Revue canadienne de nursing oncologique.

Association of hospital and physician case volumes with cardiac monitoring and cardiotoxicity during adjuvant trastuzumab treatment for breast cancer: a retrospective cohort study.

G. Tomlinson, A. Yan, M. Trudeau, 2016, CMAJ open.

High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome

I. G. Fantus, P. Goodwin, K. Pritchard, 2009, Breast Cancer Research and Treatment.

Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients

R. Jong, B. Fitzgerald, M. Clemons, 2009, Breast Cancer Research and Treatment.

Docetaxel: a review of its pharmacology and clinical activity.

M. Trudeau, 1996, The Canadian journal of oncology.

Utilization and costs of home care for patients with colorectal cancer: a population-based study.

Ning Liu, Refik Saskin, Joan Porter, 2014, CMAJ open.

Predicting breast cancer response to neoadjuvant chemotherapy using pretreatment diffuse optical spectroscopic texture analysis

Ali Sadeghi-Naini, Mehrdad J Gangeh, Lakshmanan Sannachi, 2017, British Journal of Cancer.

The association between the transfer of emergency department admitted patients to inpatient hallways and outcomes of oncology patients

M. Trudeau, S. Singh, K. Imrie, 2015 .

Dynamic optimization of chemotherapy outpatient scheduling with uncertainty

J. Christopher Beck, Michael W. Carter, Shoshana Hahn-Goldberg, 2014, Health Care Management Science.

Detection of later stage breast cancer in First Nations women in Ontario, Canada.

M. Trudeau, A. Sheppard, A. Chiarelli, 2010, Canadian journal of public health = Revue canadienne de sante publique.

Ascertaining Prognosis for Breast Cancer in Node‐Negative Patients with Innovative Survival Analysis

K. Pritchard, D. McCready, M. Trudeau, 2006, The breast journal.

Diffuse optical spectroscopy evaluation of treatment response in women with locally advanced breast cancer receiving neoadjuvant chemotherapy.

Hany Soliman, Ali Sadeghi-Naini, Gregory J Czarnota, 2012, Translational oncology.

Factors Affecting Distant Disease-Free Survival for Primary Invasive Breast Cancer: Use of a Log-Normal Survival Model

I. Andrulis, D. McCready, J. Chapman, 2000, Annals of Surgical Oncology.

Chronobiological factors for compassion satisfaction and fatigue among ambulatory oncology caregivers

M. Fitch, M. Trudeau, M. Ralph, 2017, Chronobiology international.

Chemotherapy-Response Monitoring of Breast Cancer Patients Using Quantitative Ultrasound-Based Intra-Tumour Heterogeneities

Michael C. Kolios, W. Tran, K. Pritchard, 2017, Scientific Reports.

Association of young age and chemotherapy with psychosocial distress and health-related quality of life (HRQOL) during the first year after breast cancer (BC)

P. Goodwin, K. Pritchard, M. Trudeau, 2004 .

ACTR-42. INITIAL EXPERIENCE OF BLOOD-BRAIN BARRIER OPENING FOR CHEMOTHERAPEUTIC-DRUG DELIVERY TO BRAIN TUMOURS BY MR-GUIDED FOCUSED ULTRASOUND

K. Hynynen, N. Lipsman, A. Bethune, 2017 .

Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration

F. Dionne, A. Denburg, Marianne Taylor, 2023, Current Oncology.

Burnout among oncology nurses: Influence of chronotype and sleep quality

M. Trudeau, M. Ralph, Daniela Bellicoso, 2014 .

Zoledronic Acid as Adjuvant Therapy in Combination with Adjuvant Endocrine Therapy for Premenopausal Women with Early-Stage Hormone Receptor Positive Breast Cancer

A. Eisen, M. Clemons, M. Trudeau, 2013 .

Evidence-based Series 1-9 IN REVIEW Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women with Early Stage Invasive Breast Cancer

A. Eisen, M. Trudeau, J. Franek, 2014 .

Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated.

B. Leyland-Jones, D. Cameron, A. Wardley, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer.

M. Trudeau, 1999, Seminars in oncology.

Neutropenia Induced by Aminoglutethimide in Breast Cancer

M. Trudeau, J. Steinberg, 1993, Journal of the Royal Society of Medicine.

Quantitative ultrasound radiomics using texture derivatives in prediction of treatment response to neo-adjuvant chemotherapy for locally advanced breast cancer

W. Tran, A. Eisen, F. Wright, 2020, Oncotarget.

Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?

K. Hess, L. Pusztai, C. Kelly, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

RNA Disruption and Drug Response in Breast Cancer Primary Systemic Therapy.

K. Pritzker, D. Generali, M. Trudeau, 2015, Journal of the National Cancer Institute. Monographs.

Decisional Support throughout the Cancer Journey for Older Women Diagnosed with Early Stage Breast Cancer: A Single Institutional Study

A. Kiss, E. Warner, D. Feldman-Stewart, 2014, Journal of Cancer Education.

Comparative Effectiveness and Safety of Pertuzumab and Trastuzumab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy for Treatment of Metastatic Breast Cancer

C. Earle, M. Trudeau, Ning Liu, 2022, JAMA network open.

Use of Alternative Therapy in Postmenopausal Breast Cancer Patients Treated with Tamoxifen after Surgery

A. Fyles, S. Narod, D. McCready, 2004, The Breast Journal.

National Survey Among Radiation Oncology Residents Related to Their Needs in Geriatric Oncology

S. Alibhai, François Gallant, M. Giuliani, 2019, Journal of Cancer Education.

Meeting the needs of the aging population: The canadian network on aging and cancer—report on the first network meeting, 27 april 2016

S. Mohile, S. Alibhai, E. Szumacher, 2017 .

Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study

Nir Lipsman, Kullervo Hynynen, Arjun Sahgal, 2019, Scientific Reports.

Global variations in reimbursement of new cancer therapeutics: Improving access through risk-sharing agreements.

M. Trudeau, B. Godman, S. Gavura, 2010 .

A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22

R. Jong, Lei Han, M. Clemons, 2015, SpringerPlus.

Long-term risk of heart failure associated with adjuvant trastuzumab in breast cancer patients.

Kelvin K. W. Chan, C. Earle, G. Tomlinson, 2014 .

Management of ductal carcinoma in situ of the breast. Provincial Breast Cancer Disease Site Group.

T. Whelan, F. O'Malley, D. McCready, 1998, Cancer prevention & control : CPC = Prevention & controle en cancerologie : PCC.

An improved statistical approach: can it clarify the role of new prognostic factors for breast cancer?

W. Hanna, K. Pritchard, D. McCready, 1996, European journal of cancer.

Left ventricular function following adjuvant chemotherapy for breast cancer: The NCIC CTG MA5 experience.

D. Tu, W. Parulekar, K. Pritchard, 2006, Journal of Clinical Oncology.

R. Kerbel, R. Buckman, J. Slingerland, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated.

B. Leyland-Jones, D. Cameron, A. Wardley, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A comparison of all-subset Cox and accelerated failure time models with Cox step-wise regression for node-positive breast cancer

K. Pritchard, D. McCready, J. Chapman, 2005, Breast Cancer Research and Treatment.

Quantitative Ultrasound Evaluation of Tumor Cell Death Response in Locally Advanced Breast Cancer Patients Receiving Chemotherapy

Michael C. Kolios, M. Yaffe, S. Verma, 2013, Clinical Cancer Research.

Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.

M. Trudeau, K. Chan, J. Truong, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Management of Ductal Carcinoma in Situ of the Breast: A Clinical Practice Guideline

D. McCready, M. Trudeau, C. Holloway, 2006 .

A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer

E. Winer, Zhou Zhu, P. Morris, 2020, Clinical Cancer Research.

Circulating tumour cells (CTC) in breast cancer patients enumerated after filtration enrichment: Evaluation of prognostic significance

Liying Zhang, M. Trudeau, Alexander Marks, 2005 .

Biomarker Profiles in Trastuzumab (T) Refractory HER2+ Inflammatory Breast Cancer (IBC) That Predict for Survival Benefit from Lapatinib (L) Monotherapy.

C. Swanton, S. Stein, S. Johnston, 2009 .

Novel MRI-guided focussed ultrasound stimulated microbubble radiation enhancement treatment for breast cancer

Michael C. Kolios, G. Stanisz, W. Tran, 2023, Scientific reports.